Olaparib Intermedia CAS 763114-26-7 Puritas ≥98.5% Factory

Description:

Nomen chemicum: 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl) methyl) acidum benzoicum

CAS: 763114-26-7

Puritas: ≥98.5%

Aspectus: Yellow ad Off-White pulveris

Intermedium de Olaparib (CAS 763113-22-0) curatione cancri ovarii germlini BRCA mediatae provectioris

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Descriptio:

Chemical Properties:

Nomen chemicum 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl) methyl) acidum benzoicum
Synonyma 2-Fluoro-5-[(4-oxo-3H-phthalazin-1-yl) methyl] acidum benzoicum
CAS Number 763114-26-7
CATTUS Number RF-PI450
Stock Status In Stock, Productio Ascendite ad Tons
Formulae hypotheticae C16H11FN2O3
M. Pondus 298.27
Brand Ruifu Chemical

Specifications:

Item Specifications
Aspectus Yellow ad Off-White pulveris
Assay ≥98.5%
Humor (KF) ≤0.50%
Totalis immunditias ≤1.5%
Test Standard Enterprise Standard
Consuetudinem Medium Olaparib (CAS: 763113-22-0)

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard Drum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

1

FAQ:

Applicatio:

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl) methyl) acidum benzoicum (CAS: 763114-26-7) media adhibetur in synthesi Olaparib (CAS: 763113-22. -0).Olaparib, venales ab AstraZeneca sub noto nomine Lynparza, in USA mense Decembri 2014 probatus est ut iaculi, unius agentis therapiae ad curationem cancri ovarii germlini BRCA mediati progressi. Olaparib, primum a KuDOS pharmaceuticis et postea ab AstraZeneca evolvit. functiones polymerases polymeraseos ADP inhibitoris et pro aegris qui tres vel plures curationes chemotherapy receperunt, specifice approbata est.In iudiciis clinicis medicamento diuturna progressione gratuita superstes est aegris recurrente seroso ovarii cancri platino-sensitivo laborantibus.Olaparib etiam nunc in variis gradibus investigationis in curatione pectoris, gastrici, prostate, pancreatici et non-magna pulmonis cellulae cancri est.

Epistulam tuam hic scribe et mitte nobis